Comprehensive lipidomics reveals phenotypic differences in hepatic lipid turnover in ALD and NAFLD during alcohol intoxication

Israelsen, Mads; Kim, Min; Suvitaival, Tommi; Madsen, Bjørn Stæhr; Hansen, Camilla Dalby; Torp, Nikolaj; Trost, Kajetan; Thiele, Maja; Hansen, Torben; Legido-Quigley, Cristina; Krag, Aleksander; MicrobLiver Consortium

Published in:
JHEP Reports

DOI:
10.1016/j.jhepr.2021.100325

Publication date:
2021

Document version:
Final published version

Document license:
CC BY-NC-ND

Citation for published version (APA):
Israelsen, M., Kim, M., Suvitaival, T., Madsen, B. S., Hansen, C. D., Torp, N., Trost, K., Thiele, M., Hansen, T., Legido-Quigley, C., Krag, A., & MicrobLiver Consortium (2021). Comprehensive lipidomics reveals phenotypic differences in hepatic lipid turnover in ALD and NAFLD during alcohol intoxication. JHEP Reports, 3(5), [100325]. https://doi.org/10.1016/j.jhepr.2021.100325

Go to publication entry in University of Southern Denmark's Research Portal

Terms of use
This work is brought to you by the University of Southern Denmark. Unless otherwise specified it has been shared according to the terms for self-archiving. If no other license is stated, these terms apply:

- You may download this work for personal use only.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying this open access version

If you believe that this document breaches copyright please contact us providing details and we will investigate your claim. Please direct all enquiries to puresupport@bib.sdu.dk
Comprehensive lipidomics reveals phenotypic differences in hepatic lipid turnover in ALD and NAFLD during alcohol intoxication

Authors
Mads Israelsen, Min Kim, Tommi Suvitaival, Bjørn Stæhr Madsen, Camilla Dalby Hansen, Nikolaj Torp, Kajetan Trost, Maja Thiele, Torben Hansen, Cristina Legido-Quigley, Aleksander Krag

Correspondence
Aleksander.Krag@rsyd.dk (A. Krag).

Graphical abstract

Study design

Changes in lipidome profile during alcohol intoxication

Conclusion

Lipidomics reveals reduced hepatic lipid turnover in NAFLD compared to ALD and healthy controls during alcohol intoxication.

ALD, alcohol related liver disease; NAFLD, non-alcoholic fatty liver disease

Highlights

- Alcohol intoxication induces rapid changes in the profile of circulating lipids.
- Alcohol has a profound effect on monosaturated fatty acids.
- Triglyceride clearance is suppressed in NAFLD during alcohol intoxication.
- Hepatic lipid turnover differentiates ALD and NAFLD during alcohol intoxication.
- A suppressed metabolic response may explain why alcohol is particularly harmful in NAFLD.

Lay summary

We report that alcohol induces hepatic extraction of free unsaturated fatty acids and lysophosphatidylcholines, hepatotoxic lipids which have not been previously associated with alcohol-induced liver injury. We also found that individuals with non-alcoholic fatty liver disease have reduced lipid turnover during alcohol intoxication when compared with people with alcohol-related fatty liver disease. This may explain why alcohol is particularly more harmful in people with non-alcoholic fatty liver and why elevated BMI and alcohol have a synergistic effect on the risk of liver-related death.

https://doi.org/10.1016/j.jhepr.2021.100325
Comprehensive lipidomics reveals phenotypic differences in hepatic lipid turnover in ALD and NAFLD during alcohol intoxication

Mads Israelsen,1,2,† Min Kim,4,† Tommi Suvitaival,4 Bjørn Stæhr Madsen,1,2 Camilla Dalby Hansen,1,2 Nikolaj Torp,1,2† Kajetan Trost,2 Maja Thiele,1,2 Torben Hansen,5 Cristina Legido-Quigley,4,6,† Aleksander Krag1,2,‡, on behalf of the MicrobLiver Consortium

1Department of Gastroenterology and Hepatology, Odense University Hospital, Odense C, Denmark; 2Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense C, Denmark; 3OPEN Open Patient data Explorative Network, Faculty of Health Sciences, University of Southern Denmark, Odense C, Denmark; 4Steno Diabetes Center Copenhagen, Gentofte, Denmark; 5Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark; 6King’s College London, London, UK

JHEP Reports 2021. https://doi.org/10.1016/j.jhepr.2021.100325

Background & Aims: In experimental models, alcohol induces acute changes in lipid metabolism that cause hepatocyte lipoapoptosis and inflammation. Here we study human hepatic lipid turnover during controlled alcohol intoxication.

Methods: We studied 39 participants with 3 distinct hepatic phenotypes: alcohol-related liver disease (ALD), non-alcoholic fatty liver disease (NAFLD), and healthy controls. Alcohol was administrated via nasogastric tube over 30 min. Hepatic and systemic venous blood was sampled simultaneously at 3 time points: baseline, 60, and 180 min after alcohol intervention. Liver biopsies were sampled 240 min after alcohol intervention. We used ultra-high performance liquid chromatography mass spectrometry to measure levels of more than 250 lipid species from the blood and liver samples.

Results: After alcohol intervention, the levels of blood free fatty acid (FFA) and lysophosphatidylcholine (LPC) decreased, while triglyceride (TG) increased. FFA was the only lipid class to decrease in NAFLD after alcohol intervention, whereas LPC and FFA decreased and TG increased after intervention in ALD and healthy controls. Fatty acid chain uptake preference in FFAs and LPCs were oleic acid, linoleic acid, arachidonic acid, and docosahexaenoic acid. Hepatic venous blood FFA and LPC levels were lower when compared with systemic venous blood levels throughout the intervention. After alcohol intoxication, liver lipidome in ALD was similar to that in NAFLD.

Conclusions: Alcohol intoxication induces rapid changes in circulating lipids including hepatic turnaround from FFA and LPC, potentially leading to lipoapoptosis and steatohepatitis. TG clearance was suppressed in NAFLD, possibly explaining why alcohol and NAFLD are synergistic risk factors for disease progression. These effects may be central to the pathogenesis of ALD.

Clinical Trials Registration: The study is registered at Clinicaltrials.gov (NCT03018990).

Lay summary: We report that alcohol induces hepatic extraction of free unsaturated fatty acids and lysophosphatidylcholines, hepatotoxic lipids which have not been previously associated with alcohol-induced liver injury. We also found that individuals with non-alcoholic fatty liver disease have reduced lipid turnover during alcohol intoxication when compared with people with alcohol-related fatty liver disease. This may explain why alcohol is particularly more harmful in people with non-alcoholic fatty liver and why elevated BMI and alcohol have a synergistic effect on the risk of liver-related death.© 2021 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Alcohol is the leading etiology of cirrhosis and is associated with high morbidity and mortality.1 From 1999 to 2016 the USA experienced a 2–10% annual increase in mortality as a result of alcohol-related liver disease (ALD).2 Worldwide 20% of all people have at least 1 heavy drinking episode per month3 and weekly heavy drinking episodes are seen in 13% of people in the USA.4 Heavy drinking episodes are associated with higher risk of developing chronic liver injury and alcohol-related cirrhosis,5 with a particularly high risk in obese people.6–8 Alcohol-induced lipo-toxicity is an emerging area and it has an important role in the pathogenesis of alcohol-related steatohepatitis. Hepatic alcohol detoxification leads to the formation of toxic metabolites and hepatic steatosis, and it is well-established that alcohol causes hepatic accumulation of free fatty acids (FFAs) by blocking mitochondrial beta-oxidation.9 However, experimental models suggest a more complex interaction...
between alcohol and hepatic lipid metabolism; alcohol increases the hepatic uptake of FFAs, alcohol has different effects on distinct types of FFA (short vs. long-chain and saturated vs. unsaturated), and alcohol may also affect other lipid classes including lysophosphatidylcholines (LPCs) that can induce lipotoxicity.9,10 Furthermore, animal models reveal that a high-fat diet increases the susceptibility of alcohol-induced injury and the combination leads to an increased rate of progression of chronic liver injury.11,12

Although experimental studies have revealed mechanistic knowledge, we lack human studies that can aid the clinical understanding of lipid metabolism in relation to alcohol intoxication. To investigate the translation of experimental findings to humans, we developed a study where participants were given a controlled amount of alcohol to replicate alcohol intoxication (Fig. 1A). We recruited participants with 3 different hepatic phenotypes: healthy controls, ALD, and non-alcoholic fatty liver disease (NAFLD). Blood samples were collected from hepatic and systemic veins before and after alcohol intoxication from all 3 hepatic phenotypes. Liver biopsy samples were collected by the end of alcohol intoxication from participants with ALD and NAFLD. Comprehensive lipidomic analyses were performed on these blood and liver tissue samples (Fig. 1B). Our overall aims were to (1) explore the effects of alcohol intoxication on the hepatic venous blood lipid profile, (2) test whether alcohol intoxication causes different reactions in people with ALD or

Fig. 1. Schematic study design and lipidome workflow. (A) Study design: for the baseline visit, we invited 40 individuals with 3 distinct hepatic phenotypes: 10 healthy controls, 15 with ALD, and 15 with NAFLD. One ALD participant was subsequently excluded owing to protocol violation by consuming alcohol within 48 h before the alcohol intervention. The remaining 39 participants underwent the alcohol intervention: blood was sampled at time 0 min, and alcohol was subsequently instilled over 30 min. Blood was sampled again after 60 and 180 min. *Transjugular liver biopsies were collected after 240 min in participants with ALD and NAFLD. (B) Lipidome workflow: lipid levels (n = 252) were measured using ultra-high-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UHPLC-QTOFMS). First, we explored the average level of 13 distinct lipid classes from hepatic venous blood to identify which lipid class changed in its level over time after alcohol intervention. We used longitudinal mixed effect models to investigate 3 different fixed effects: (1) ‘time’, (2) ‘time*phenotype’, and (3) ‘time*blood site’. Fixed effect of ‘time’ allowed us to identify lipid classes that changed in their levels after alcohol intervention. Fixed effect of ‘time*phenotype’ allowed us to see whether levels of 13 lipid classes were different between the hepatic phenotypes before and after alcohol intervention. Fixed effect of ‘time*blood site’ allowed us to see whether levels of 13 lipid classes were different between 2 blood vein sites (systemic vs. hepatic) before and after alcohol intervention. Finally, we investigated 252 individual lipid species using the same approach where fixed effects were (1) ‘time’, (2) ‘time*phenotype’, and (3) ‘time*blood site’. In all models, random effect was the individual participant. ALD, alcohol-related liver disease; NAFLD, non-alcoholic fatty liver disease.
NAFLD and healthy controls, and (3) explore differences between hepatic and systemic blood lipid profiles as well as liver lipid profiles.

**Patients and methods**

**Participants**

Age-matched individuals with 3 hepatic phenotypes were included: (1) healthy controls with no sign of liver disease; (2) individuals with ALD, and (3) individuals with NAFLD. Potential participants received written and oral information followed by a pre-investigation consultation with a physician involved in the study. All investigations were performed at Odense Liver Research Centre. The study was approved by the Ethical Committee of Southern Denmark (S-20160083), registered at ClinicalTrials.gov (NCT03018990), and complied with the Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects. All participants signed an informed consent. Participants were recruited through the Odense Liver Research Centre with inclusion criteria of age 18–75 years, body weight >50 kg, capable to be abstinent for 48 h before the investigations, and signed informed consent. Individuals with ALD should be regularly drinking and have a prior or ongoing heavy alcohol intake (males >36 g alcohol/day, females >24 g alcohol/day), biopsy-proven liver fibrosis on a previous liver biopsy, and histological features in keeping with ALD. No participants with ALD were abstinent from alcohol or had a desire to become abstinent from alcohol. Individuals with NAFLD should have biopsy-proven liver fibrosis, histological features in keeping with NAFLD, and no history of heavy alcohol intake. Healthy controls should have normal liver stiffness, BMI <30 kg/m², normal biochemistry, and no history of heavy alcohol intake. General exclusion criteria were cirrhosis on a previous liver biopsy, competing liver disease of other aetiology, insulin-dependent diabetes mellitus, pregnancy or breastfeeding, antibiotic use within the previous 4 weeks, and all types of cancer.

**Investigations**

The investigations were initiated in the morning, after 8 h fasting and minimum of 48 h abstinence from alcohol. Under local anaesthesia, a catheter was placed in a hepatic vein via the right jugular vein and inferior vena cava for sampling hepatic venous blood.13 Another catheter was placed in the jugular vein for systemic blood sampling. Radiography (X-ray) was used to ensure correct placement of the catheters before blood sampling.

**Alcohol intervention**

Ethanol was instilled through a nasogastric tube and was 40% pure ethanol in 9 mg/ml NaCl produced at the hospital pharmacy. Participants received a dose of 2.5 ml of 40% ethanol per kg body weight, instilled over 30 min by infusion pump. To avoid severe intoxication in participants with high body fat percentage, the dose was adjusted by 0.5 ml for each kg body weight encountered from BMI above 25 kg/m².

**Blood sampling**

Blood was sampled simultaneously from a hepatic vein and the right external jugular vein at baseline (time 0, just before alcohol intervention), after 60 min, and after 180 min. The Department of Biochemistry and Pharmacology at Odense University Hospital analysed serum alcohol concentrations and routine biochemistry according to standard operating procedures. Blood samples for lipidome analysis were collected in lithium heparin tubes chilled in crushed ice and water. Within 1 h after sampling, we centrifuged and pipetted the samples to secondary tubes and stored them at -80°C. A flowchart of the clinical set-up can be found in Fig. 1.

**Liver biopsy sampling**

Transjugular liver biopsies were performed using a Tru-Cut biopsy needle in participants with ALD and NAFLD 240 min after alcohol instillation. The first piece of liver tissue from each participant was immediately stored in formalin 4% and sent for histopathological assessment and scored according to the non-alcoholic steatohepatitis Clinical Research Network system with regards to fibrosis, steatosis, inflammation, and ballooning. The second piece of tissue was stored immediately in dry tubes at -80°C until lipidome analysis.

**Lipidome analysis**

Sample preparation for lipidomic analysis has been described elsewhere16,17 and is explained in detail in Supplementary Methods 1. Briefly, a plasma sample (10 µl) was mixed with 10 µl 0.9% w/v NaCl (aq) and internal standards containing 120 µl of chloroform/methanol (2:1) mixture. The lipid containing chloroform was analysed using ultra-high performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UHPLC-QTOF/MS). Samples were analysed in a randomised order, with quality control (QC) pooled plasma samples at regular intervals throughout the run (n = 30 for both positive and negative ionisation).

For liver tissue, the needle biopsy sample was first converted into powdered forms by crushing samples using a Covaris CryoPrep impactor CP02. Approximately 2 mg of powdered tissue sample were used for lipid extraction (exact mass was measured and used for the post-processing normalisation step later). The sample was mixed with internal standards containing 480 µl of chloroform/methanol (2:1) mixture. The lipid containing chloroform was analysed in the same manner as the blood samples. The lipidomics data were pre-processed with MZmine2,18 and lipid features were then normalised to internal standards and log transformed. Liver samples were further normalised to the exact weight used during lipid extraction. We excluded lipid features with >20% missingness across all samples and relative standard deviation values >20% across QC samples. The lipid features were then standardised (scaled) to have a mean of 0 and a standard deviation of 1×10³. The data were cross-matched with an in-house library where 252 lipids from 13 different lipid classes were identified in blood samples, whereas 316 lipids from 14 different lipid classes were identified in liver tissue samples at level 1 and 2 lipid identification levels.

**Statistical analysis**

Participants’ baseline characteristics are reported as mean and SD, counts and proportion, or medians and IQR depending on the distribution. For blood lipidomic analysis, we applied longitudinally mixed effect regression models with participants as a random effect to investigate changes in circulating lipid contents after alcohol intake.

First, we explored the average level of 13 distinct lipid classes from hepatic venous blood to identify which lipid classes
changed in level over time after alcohol intervention. For this, we derived average levels from each lipid class and built mixed models between levels of 13 lipid classes and 3 different fixed effects: (1) ‘time’, (2) ‘time’*phenotype, and (3) ‘time’*blood site. Fixed effect of ‘time’ allowed us to investigate changes in circulating lipid content after alcohol intervention. From these models we derived estimate coefficient values (representing changes in relative levels per minute) and their corresponding p values. The fixed effect of ‘time’*phenotype allowed us to see whether levels of 13 lipid classes were different between phenotypes at baseline (before alcohol intervention) and whether estimate coefficient values of lipid classes differed between the 3 phenotypes. The fixed effect of ‘time’*blood site allowed us to see whether baseline levels and estimate coefficient values of the 13 lipids classes differed between the 2 blood vein sites (systemic vs. hepatic).

From the 13 lipid classes, we investigated 252 individual lipid species. We used the same approach as above where fixed effects were (1) ‘time’, (2) ‘time’*phenotype, and (3) ‘time’*blood site. In all models, random effect was the individual participant. We report the significant lipids after Bonferroni correction for multiple testing. Mixed models were carried out in R 3.6.0 (R Foundation for Statistical Computing, Vienna, Austria) using the ‘nlme’ package.

Lipid levels (n = 316, 14 lipid classes) from liver biopsy samples were available from 14 participants with ALD and 15 participants with NAFLD after alcohol intervention. We investigated the effect of alcohol intervention between ALD and NAFLD liver lipids by utilising a logistic regression model where the age of participants at the time of sampling was adjusted. Regression modelling was carried out in R 3.6.0. A schematic workflow of the of the lipidome data analysis is shown in Fig. 1.

## Results

### Participants

Baseline investigations were performed on 40 individuals from November 2016 to November 2018, however, 1 participant with ALD was subsequently excluded because of protocol violation by consuming alcohol within 48 h of the alcohol intervention. Table 1 shows the participants’ baseline characteristics. The mean age was 54 ± 11 years, 62% were males, and there were no significant differences between the groups. Median alcohol consumption was 60 g/day in those with ALD and below 12 g/day in those with NAFLD and healthy controls (p < 0.001). Participants with NAFLD had higher BMI, higher haemoglobin A1c, and lower HDL cholesterol than those with ALD and healthy controls (p < 0.01). There was no difference between the ALD and NAFLD groups with regards to liver blood tests and liver histopathology (Table 1). Overall, 55% had significant fibrosis (≥F2), 48% had moderate or severe steatosis (≥S2), and the median NAFLD

### Table 1. Participant characteristics.

| Characteristics               | All       | Controls  | ALD       | NAFLD     | p value |
|-------------------------------|-----------|-----------|-----------|-----------|---------|
| Participants, n               | 39        | 10        | 14        | 15        |         |
| Male sex, n                   | 24 (62%)  | 5 (50%)   | 12 (86%)  | 7 (47%)   | 0.066   |
| Age, yr                       | 54 ± 11   | 53 ± 10   | 57 ± 11   | 53 ± 12   | 0.930   |
| Weight, kg                    | 87 (74–104) | 75 (67–84) | 85 (74–104) | 99 (86–108) | 0.006   |
| BMI, kg/m²                    | 29 (25–32) | 25 (23–27) | 28 (23–32) | 32 (30–41) | <0.001  |
| Type 2 diabetes, n            | 14 (36%)  | 0 (0%)    | 4 (29%)   | 10 (67%)  | 0.002   |
| Metabolic syndrome, n         | 18 (46%)  | 0 (0%)    | 6 (43%)   | 12 (80%)  | <0.001  |
| Daily alcohol consumption, g  | 6 (0–9)   | 12 (0–12) | 60 (24–120) | 0 (0–0)  | <0.001  |

### Biochemistry

| Parameter                      | All         | Controls    | ALD         | NAFLD       | p value |
|-------------------------------|-------------|-------------|-------------|-------------|---------|
| Platelet, 10³/L               | 221 (190–270) | 210 (169–228) | 216 (105–244) | 252 (196–303) | 0.256   |
| INR                           | 1 (0.9–11)  | 1.1 (1–11)  | 1 (0.9–11)  | 1 (0.9–11)  | 0.192   |
| Albumin, g/L                  | 45 (42–47)  | 46.5 (40–48) | 43 (41–46)  | 45 (43–48)  | 0.141   |
| ALT, U/L                      | 36 (23–58)  | 26 (17–33)  | 44 (27–71)  | 44 (26–65)  | 0.085   |
| AST, U/L                      | 29 (25–58)  | 23 (22–28)  | 49 (29–79)  | 29 (24–61)  | 0.007   |
| GGT, U/L                      | 62 (23–138) | 22 (15–26)  | 197 (89–635) | 65 (45–90)  | <0.001  |
| Bilirubin, µmol/L             | 10 (7–13)   | 10 (9–13)   | 13 (7–19)   | 10 (6–13)   | 0.490   |

### Metabolic parameters

| Parameter                      | All         | Controls    | ALD         | NAFLD       | p value |
|-------------------------------|-------------|-------------|-------------|-------------|---------|
| Fasting P-glucose, mmol/L     | 6.2 (5.5–7.0) | 5.7 (5.5–6.1) | 6.5 (5.6–7)  | 6.7 (6.2–7)  | 0.014   |
| HbA1c, mmol/mol               | 38 (34–45)  | 35 (31–37)  | 37 (31–40)  | 46 (40–55)  | <0.001  |
| Insulin, pmol/L               | 93 (44–183) | 43 (31–47)  | 78 (46–217) | 171 (116–188) | 0.001   |
| HOMA-IR                       | 5.3 (1.7–8.7) | 1.6 (1.2–1.8) | 3.2 (1.7–10.3) | 7.0 (5.2–8.8) | <0.001  |
| HDL cholesterol, mmol/L       | 1.2 (1–1.6)  | 1.5 (1–1.2)  | 1.5 (1–1.6)  | 1.1 (0.9–1.3) | 0.005   |
| LDL cholesterol, mmol/L       | 2.6 (2.2–3.6) | 3.1 (2.5–4.3) | 2.4 (2.2–3.1) | 2.6 (1.3–3.6) | 0.234   |
| Total cholesterol, mmol/L     | 4.8 (4.2–6.0) | 5.3 (4.5–6)  | 4.9 (4.4–6.2) | 4.4 (3.8–5.6) | 0.236   |
| Triglycerides, mmol/L         | 1.36 (0.78–2.2) | 0.80 (0.72–1.2) | 1.55 (0.85–2.5) | 1.45 (0.82–3.3) | 0.033   |

### Liver parameters

| Parameter                      | All         | Controls    | ALD         | NAFLD       | p value |
|-------------------------------|-------------|-------------|-------------|-------------|---------|
| Fibrosis stage (0/1/2/3/4), n | –           | –           | 2/5/5/1/1   | 1/5/7/1/1   | –       |
| Steatosis grade (0/1/2/3), n   | –           | –           | 0/5/2/4     | 0/7/5/3     | –       |
| NAFLD activity score          | –           | –           | 3 (1–4)     | 3 (2–4)     | –       |
| Liver stiffness by TE, kPa     | 8.9 (4.9–11) | 4.6 (3.9–5.0) | 9.0 (5.9–11) | 10.4 (9.5–11) | <0.001  |

Data are presented as means (SD), medians (IQR), or counts (frequencies). Values of p are obtained from comparisons between the 3 groups using Kruskal-Wallis and Chi-square tests. Comparisons between 2 groups are obtained using rank sum and Fisher’s exact test with significance level <0.05 and marked as follows: ‘significant difference between ALD and NAFLD; *significant difference between controls and ALD/NAFLD. Classification of metabolic syndrome was performed according to the International Diabetes Federation criteria.

ALD, alcohol-related liver disease; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transferase; HOMA-IR, Homeostatic Model Assessment of Insulin Resistance; NAFLD, non-alcoholic fatty liver disease; P-glucose, plasma glucose; TE, transient elastography.
Fig. 2. Lipid profile of 3 hepatic phenotypes. (A) Boxplots showing FFA, LPC, and TG levels from hepatic vein for the 3 hepatic phenotypes. These 3 lipid classes were selected here because their levels changed after alcohol intervention in at least 1 phenotype (Table 2). FFA showed significant changes over time in Control, ALD, and NAFLD phenotypes, while LPC showed significant changes over time in the Control phenotype. TG showed significant changes over time in ALD and NAFLD phenotypes. Significances were based on p < 0.0039. (B) Forrest plot showing magnitude of change after alcohol intervention (estimate coefficients derived from mixed models) for all 13 lipid classes from hepatic vein in each hepatic phenotype. (C) Boxplots comparing FFA, LPC, and TG levels in hepatic and systemic veins. The lines connect the means of boxes. ALD, alcohol-related liver disease; CTL, healthy control; FFA, free fatty acid; LPC, lysophosphaticidylcholine; NAFLD, non-alcoholic fatty liver disease; TG, triglyceride.
activity score was 3. All the healthy controls had normal liver stiffness (<6 kPa).

**Alcohol intervention**

All participants received the scheduled alcohol dose according to the protocol. The mean serum alcohol concentration was 0 ± 0 mmol/l (0.00 ± 0 g/dl) at baseline, peaked at 34 ± 4 mmol/l (0.16 ± 0.2 g/dl) after 60 min, and decreased to 21 ± 3 (0.10 ± 0.1 g/dl) mmol/ after 180 min (p < 0.001). Only mild transient symptoms commonly seen in relation to alcohol intake were observed.

**Hepatic venous lipid classes before and after alcohol intervention**

Before the alcohol intervention, healthy controls had lower hepatic venous triglyceride (TG) levels compared with those with ALD and NAFLD (Fig. 2A and Table 2). Alcohol intervention led to significant reductions in levels of FFA (−39.42 units/min, p < 0.0001) and LPC (−14.08 units/min, p = 0.0002) (Table 3), but not for other lipid classes. The effect of alcohol intervention on all 13 lipid classes is summarised in Table S1.

**Effect of alcohol intervention by phenotype on hepatic venous lipid classes**

Alcohol caused significant reductions in hepatic venous FFA levels in individuals with all 3 hepatic phenotypes (Fig. 2B): healthy controls (−31.02 units/min, p = 0.0030), ALD (−44.36 units/min, p = 0.0002), and NAFLD (−40.41 units/min, p = 0.0004) (Fig. 2B and Table 3). In contrast, LPC decreased only in healthy controls (−23.96 units/min, p < 0.0001) and in ALD (−20.97 units/min, p = 0.0041) (Table 3). Hepatic TG levels increased significantly in healthy controls (+25.20 units/min, p = 0.0013) and in ALD (+17.52 units/min, p = 0.0034) but not in NAFLD (-1.95 units/min, p = 0.855) (Fig. 2B and Table 3).

Estimate coefficient values for each lipid class and between-group comparisons are provided in Tables S1 and S2. Relative levels of each lipid class are provided in Table S3.

**Hepatic vs. systemic venous blood**

Before alcohol intervention, the level of FFAs in individuals of all 3 hepatic phenotypes was significantly lower in hepatic venous blood than in systemic venous blood (Fig. 2C and Table 2). However, the rates at which lipid classes changed during alcohol intervention (estimate coefficient values) did not differ between hepatic and systemic venous blood for any of the lipid classes (Table S1).

**Single lipid levels before and after alcohol intervention**

Twenty-four of 252 individual lipids changed significantly in hepatic venous blood after alcohol intervention at Bonferroni level of p < 1.98 × 10⁻⁴ (Fig. 3A). Estimated coefficient values for these 24 lipids can be found in Table S4. One monounsaturated fatty acid and 3 polyunsaturated fatty acids decreased in response to alcohol: oleic acid (FFA 18:1), linoleic acid (FFA 18:2), arachidonic acid (FFA 20:4), and docosahexaenoic acid (FFA 22:6). The levels of 9 LPCs decreased, 4 of which contained the same 4 FFAs as above. The 9 LPC molecules contained oleic acid (FFA 18:1), linoleic acid (FFA 18:2), arachidonic acid (FFA 20:4), dihomo-γ-linolenic acid (FFA 20:3), docosapentaenoic acid (FFA 20:5), docosapentaenoic acid (FFA 22:5), and docosahexaenoic acid (FFA 22:6) (Fig. 3B). The alcohol intervention also led to increased levels of 1 phosphatidylcholine and 10 TG molecules.

---

Table 2. Comparison of FFA, LPC, and TG at baseline between hepatic and systemic venous blood.

| Lipid class | Average lipid levels in hepatic vein (SD), ×10² | Average lipid levels in systemic vein (SD), ×10² |
|-------------|-----------------------------------------------|-----------------------------------------------|
|             | All Controls | ALD | NAFLD | All Controls | ALD | NAFLD |
| FFA         | 12.92 (45.06) | 5.64 (48.40)† | 21.41 (28.90) | 9.85 (55.72)† | 80.21 (59.73)† | 104.92 (61.19)† | 62.15 (48.17)† | 80.60 (66.04)† |
| LPC         | 5.13 (84.72)  | 62.15 (48.17)* | 104.92 (61.19)† | 62.15 (48.17)† | 80.60 (66.04)† |
| TG          | −15.44 (76.09) | −62.15 (48.17)* | 104.92 (61.19)† | 62.15 (48.17)† | 80.60 (66.04)† |

† Difference to healthy controls at Bonferroni procedure p < 0.0039 level according to mixed model.

Table 3. Summary of mixed models showing relative changes in FFA, LPC, and TG levels from baseline to 180 min after start of alcohol intake.

| Lipid class | Hepatic vein: estimate coefficients (95% CI) | Systemic vein: estimate coefficients (95% CI) |
|-------------|-----------------------------------------------|-----------------------------------------------|
|             | All Controls | ALD | NAFLD | All Controls | ALD | NAFLD |
| FFA         | p < 0.0001   | p < 0.0001 | p < 0.0001 | p < 0.0001 | p < 0.0001 | p < 0.0001 |
| LPC         | p = 0.0002   | p = 0.0002 | p = 0.0002 | p = 0.0002 | p = 0.0002 | p = 0.0002 |
| TG          | p < 0.0001   | p < 0.0001 | p < 0.0001 | p < 0.0001 | p < 0.0001 | p < 0.0001 |

The table shows estimate coefficients (change in relative levels of lipid every minute after alcohol intervention) and their p values are shown.

ALD, alcohol-related liver disease; FFA, free fatty acid; LPC, lysophosphatidylcholine; NAFLD, non-alcoholic steatohepatitis; TG, triglyceride.

* Passed Bonferroni procedure p < 0.0039.
significant lower in healthy controls compared with those with NAFLD (Fig. S1 and Table S4). No lipids differed between the groups with ALD and NAFLD before alcohol intervention (Table S5). The 4 FFA levels were similar in healthy controls, and those with ALD and NAFLD before alcohol intervention (Fig. S1).

We then compared changes (estimate coefficient values) between the hepatic phenotypes. Fig. S1 shows TG molecules increased more profoundly in healthy controls, but only TG (44:1) showed a significant difference between healthy controls (+73.08 units/min) and the group with NAFLD (+4.40 units/min). We observed similar patterns for FFA and LPC lipids across all 3 hepatic phenotypes.

Additionally, we carried out longitudinal models in each phenotype for all individual lipids. The models summarised in volcano plots are shown in Fig. 4. In healthy controls, hepatic venous levels of 25 lipids changed after alcohol intervention (p <1.98×10^{-4}), these included the 24 lipids found from the earlier model. Two FFA and 8 LPC molecules decreased, while 14 TG molecules and 1 PC molecule increased. In those with ALD, 19 hepatic venous lipids had altered levels, 4 FFA and 4 LPC decreased, while 11 TG increased. In those with NAFLD, only 2 FFA hepatic lipids decreased after alcohol intervention.

**ALD vs. NAFLD liver lipidomics**
Liver biopsies were collected from participants with ALD and NAFLD after alcohol intervention and liver lipidomic profiles were compared, to identify different lipids levels between the 2 hepatic phenotypes. Logistic regression model showed no lipid being different between the 2 hepatic phenotypes at Bonferroni p <1.58×10^{-4} level (Fig. S3).

**Discussion**
In this first investigation in humans of how acute alcohol intoxication affects the circulating hepatic and systemic lipidome, we found that alcohol caused significantly reduced levels of LPCs and FFAs, and increased TG levels. The increase in TGs was restricted to healthy controls and those with ALD, indicating a suppressed or altered TG synthesis in those with NAFLD during acute alcohol intoxication. The TGS that increased were mostly unsaturated or monounsaturated indicating de novo lipogenesis.

Our data show a decrease in circulating LPC after alcohol intake. We hypothesise that alcohol increases hepatic LPC uptake which leads to lipopapoptosis and alcoholic steatohepatitis (Fig. 5). The role of LPC in the pathogenesis of ALD is not yet known, but i.e. LPC injections induced lobular hepatitis in mice,19 and intracellular LPCs were shown to cause caspase activation and generation of oxidative stress resulting in lipopapoptosis of hepatocytes.20,21 Human liver tissue lipidome profiling of simple non-alcoholic fatty liver vs. non-alcoholic steatohepatitis revealed that livers with steatohepatitis contain a higher amount of LPC,22 but lower circulating LPC levels are a marker of poor prognosis in participants with NAFLD.23,24 This indicates an inverse

---

**Fig. 3. Changes in lipid levels after alcohol intervention.** (A) Volcano plot showing changes in levels (mixed model estimate coefficients) for 252 lipids from hepatic vein after alcohol intervention. Statistical significance (y-axis) is plotted against the magnitude of change in the lipid levels after alcohol intervention (x-axis) to identify the most dynamic lipids that were also statistically significant. Different colours represent different lipid species, and larger dots represent the 24 lipids passing Bonferroni threshold (p <1.98×10^{-4}). (B) Forrest plot showing magnitude of change after alcohol intervention (mixed model estimate coefficients) for the 24 lipids from hepatic vein selected from Fig. 3A. Cer, ceramide; DG, diglyceride; FFA, free fatty acid; HexCer, hexosylceramide; LacCer, lactosylceramides; LPC, lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; NAFLD, non-alcoholic fatty liver disease; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PI, phosphatidylinositol; SHexCer, sulfatides hexosylceramide; SM, sphingomyelin; TG, triglyceride.

**Single lipid levels by phenotype before and after alcohol intervention**
We focused on these 24 lipids and compared their levels between the different hepatic phenotype groups at baseline. The healthy controls had significantly lower levels of all 10 TG lipids compared to those with ALD while 7 TG lipids were also significantly lower in healthy controls compared with those with NAFLD (Fig. S1 and Table S4).
relationship between circulating and intrahepatic LPC levels. In our study, the LPC species that decreased after alcohol intervention contained oleic acid (FFA 18:1), linoleic acid (FFA 18:2), arachidonic acid (FFA 20:4), and docosahexaenoic acid (FFA 22:6). These fatty acids in their free forms were also found to be lower in our study, in line with previous studies which showed alcohol intoxication induced a rapid drop in the systemic circulating FFA in healthy people and people with ALD and NAFLD-related diseases (type 2 diabetes and hypertriglyceridemia). Addition-
ally, we report 2 further novel findings in humans. Firstly, we observed that the drop in circulating FFAs was mainly driven by mono- and polyunsaturated FFAs, that is oleic acid, linoleic acid, arachidonic acid, and docosahexaenoic acid. Previous experimental studies showed alcohol intoxication induced a rapid drop in the systemic circulating FFA in healthy people and people with ALD and NAFLD-related diseases (type 2 diabetes and hypertriglyceridemia). Additionally, we report 2 further novel findings in humans.

Fig. 4. Volcano plot showing changes in levels (mixed model estimate coefficients) for 252 lipids from hepatic vein after alcohol intervention. (A) Healthy controls, (B) participants with ALD and (C) participants with NAFLD. ALD, alcohol-related liver disease; Cer, ceramide; DG, diglyceride; FFA, free fatty acid; HexCer, hexosylceramide; LacCer, lactosylceramides; LPC, lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; NAFLD, non-alcoholic fatty liver disease; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PI, phosphatidylinositol; SM, sphingomyelin; TG, triglyceride.
alcohol induces oxidation of unsaturated FFAs and that these oxidised unsaturated FFAs may contribute to the hepatic steatosis and inflammation seen in patients with ALD. Our results show that baseline levels and the acute effect of alcohol on unsaturated FFAs are similar in healthy controls, and those with ALD and NAFLD. Therefore, if unsaturated FFAs are involved in development or progression of liver disease, it must be related to either the frequent exposure of alcohol in ALD, or to a change in the subsequent hepatic processing of FFA. Interestingly, the FFA species which changed were same fatty acid chains seen in LPCs, suggesting a profound effect of alcohol on these specific fatty acid chains across 2 lipid species.

Secondly, we observed that the hepatic uptake of FFAs remained constant despite the alcohol-induced drop in circulating FFAs. This is noteworthy because hepatic FFA β-oxidation is inhibited during alcohol metabolism. Alcohol-induced suppression of hepatic FFA β-oxidation in combination with a continued high hepatic uptake of FFAs must lead to an overload of FFAs in the liver. This FFA excess in the liver is metabolised for TG synthesis and released to the circulation. This happened in patients with ALD and healthy controls where circulating TG increased in response to alcohol. In contrast, TG levels remained unaffected after alcohol intake in NAFLD. A suppressed capacity to convert excess hepatic FFA to TG during alcohol intoxication has also been reported in participants with type 2 diabetes and hypercholesterolaemia. A lack of TG synthesis in response to alcohol could indicate that NAFLD either have suppressed hepatic capacity of FFA esterification to TGs, or impaired hepatocyte secretion of TGs. Such impaired ability to remove FFAs from the liver could explain why binge drinking is particularly harmful in individuals with metabolic syndrome. This mechanism may help explain why metabolic risk factors and alcohol have synergistic effect on liver disease.

The pathogenesis of NAFLD is closely related to dyslipidaemia. In line with that, the NAFLD phenotype was significantly different to the ALD and healthy control phenotypes with respect to fasting levels of TG and LPC. However, the levels of TG and LPC in participants with ALD changed towards a lipid profile more similar to NAFLD after alcohol intake. Therefore, we speculate that during alcohol intoxication, chronic alcohol misusers with ALD have a functional circulating lipid profile similar to those with NAFLD. To support this observation of the circulating lipid levels in ALD changing towards those in NAFLD, we also looked at liver lipid profiles at 240 min in individuals with these 2 hepatic phenotypes who had undergone alcohol intervention and found no difference in lipid profiles after alcohol intoxication.

Limitations of the study warrant consideration. Firstly, all investigations in the present study were performed in the fasting state. Secondly, 38 participants (out of 39) were of European ethnicity. Thirdly, circulating lipid profiles may not directly reflect alcohol-induced lipid changes in hepatic lipid profile. Our hypothesis is derived from measurements of circulating lipid changes after alcohol intoxication without concomitant measurements of liver injury. Thus, future studies should validate if hepatic uptake of LPC leads to liver injury in relation to acute alcohol intoxication.

Despite these limitations, we investigated how alcohol intoxication impacts circulating lipid profiles in humans across 3 distinct hepatic phenotypes. Previous studies have mainly investigated acute alcohol intake in young and healthy individuals. In contrast, our participants were middle-aged with early-stage liver disease and thereby more representative for studying the pathogenesis of chronic fatty liver disease. Furthermore, the comprehensive lipidome analysis enabled us to study lipid classes not previously investigated and indeed revealed that circulating LPCs and specific fatty acid chains are also key in the metabolism of acute alcohol intake.

To conclude, alcohol intoxication induces rapid changes in the profile of circulating lipids. Alcohol has a profound effect on monosaturated fatty acids in their free form or as part of LPC species. Hepatic uptake of LPC may play a central role in the pathogenesis of ALD, whereas the suppressed metabolic response in patients with NAFLD may explain why alcohol is particularly harmful in individuals with metabolic syndrome.

Abbreviations
ALD, alcohol-related liver disease; ALT, alanine aminotransferase; AST, aspartagine aminotransferase; Cer, ceramide; CTL, healthy control; DG, diglyceride; FFA, free fatty acid; GGT, gamma-glutamyl transferase; HexCer, hexosylceramide; HOMA-IR, Homeostatic Model Assessment of Insulin Resistance; LacCer, lactosylceramides; LPC, lysophosphatidylcholine; LPE, lysophosphatidyethanolamine; NAFLD, non-alcoholic fatty liver disease; PC, phosphatidylcholine; PE, phosphatidylethanolamine; P-glucose, plasma glucose; PI, phosphatidylinositol; PL2A, phospholipase A2; QC, quality control; SHexCer, sulfatides hexosylceramide; SM, sphingomyelin; TE, transient elastography; TG, triglyceride.

Financial support
Challenge Grant “MicrobLiver”, NNFI5OC0016692, Novo Nordisk Foundation.

Conflicts of interests
All authors declare no conflicts of interests. Please refer to the accompanying ICMJE disclosure forms for further details.

Authors’ contributions
Conceptualised the study: MI, BSM, TH and AK. Collected data for the study: MI, MK, BSM, CDH, NT and KT. Performed the data analyses: MI, MK, TS, KT and CLQ. Drafted the manuscript: MI, MK, MT, CLQ and AK. All authors contributed to the manuscript with important intellectual content and approved the final version.

Data availability statement
Anonymised data available on request.

Acknowledgements
The authors thank Mie Balle Hugger, Annette Fialla, Annette Nielsen, Lotte Kappen, and Jane Brudvig-Lauridsen and the entire staff at Odense Liver Research Centre; Louise Skovborg Just and Lise Ryborg for the managing of GALAXY and MicrobLiver consortia; Mette Andreassen, Anette Tyrssted, and Lea Grip from Open Patient data Explorative Network; Professor Peter Rossing at Steno Diabetes Centre Copenhagen; Associate professor Claire Gudex from University of Southern Denmark; and the MicrobLiver consortium partners.

Supplementary data
Supplementary data to this article can be found online at https://doi.org/10.1016/j.jhepr.2021.100325.

References
Author names in bold designate shared co-first authorship
[1] Kim D, Li AA, Gadiarthi C, Khan MA, Cholankeril G, Glenn JS, et al. Changing trends in etiology-based annual mortality from chronic liver disease, from 2007 through 2016. Gastroenterology 2018; 155:1154–1163. e1153.

[2] Tapper EB, Parikh ND. Mortality due to cirrhosis and liver cancer in the United States, 1999–2016: observational study. BMJ 2018;362:k2817.

[3] Manthey J, Shield KD, Rylett M, Hasan OSM, Probst C, Rehm J. Global alcohol exposure between 1990 and 2017 and forecasts until 2030: a modelling study. Lancet 2019;393:2493–2502.

[4] Grant BF, Chou SP, Salda TD, Pickering RP, Kerridge BT, Ruan WJ, et al. Prevalence of 12-month alcohol use, high-risk drinking, and DSM-IV alcohol use disorder in the United States, 2001–2002 to 2012–2013: results from the National Epidemiologic Survey on Alcohol and Related Conditions. JAMA Psychiatry 2017;74:911–923.

[5] Ventura-Cots M, Watts AE, Bataller R. Binge drinking as a risk factor for advanced alcoholic liver disease. Liver Int 2017;37:1281–1283.

[6] Aberg F, Helenius-Hietala J, Puukka P, Jula A. Binge drinking and the risk of liver events: a population-based cohort study. Liver Int 2017;37:1373–1381.

[7] Hart CL, Morrison DS, Batty GD, Mitchell RJ, Davey Smith G. Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies. BMJ 2010;340:c1240.

[8] Aberg F, Helenius-Hietala J, Puukka P, Farkkila M, Jula A. Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population. Hepatology 2018;67:2141–2149.

[9] You M, Arteel GE. Effect of ethanol on lipid metabolism. J Hepatol 2019;70:237–248.

[10] Ibrahim SH, Hirsova P, Tomita K, Bronk SF, Wernhenburg L, Harrison SA, et al. Mixed lineage kinase 3 mediates release of C-C-C motif ligand 10-bearing chemotactic extracellular vesicles from lipotopic hepatocytes. Hepatology 2016;63:731–744.

[11] Nezvoroza YA, Boyer-Diaz Z, Cubero FJ, Gracia-Sancho J, Animal models for liver disease – a practical approach for translational research. J Hepatol 2020;73:423–440.

[12] Xu J, Lai KKY, Verlinsky A, Lugea A, French SW, Cooper MP, et al. Synergistic steatohepatitis by moderate obesity and alcohol in mice despite increased adiponectin and p-AMPK. J Hepatol 2011;55:673–682.

[13] Bosch J, Abraldes JG, Berzigotti A, Garcia-Pagan JC. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol 2006;3:573–582.

[14] Kleiner DE, Brunt EM, Van Natta M, Buhling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (Baltimore, Md) 2005;41:1313–1321.

[15] Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. The multiple-hit pathogenesis of non-alcoholic fatty liver disease. Hepatology 2016;63:731–744.

[16] Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease. J Hepatol 2009;6:573–582.

[17] Alberti KG, Zimmet P, Shaw J. Metabolic syndrome – a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med 2006;23:469–480.